|
SOBERANA 02 |
|
CIMAvax-EGF in patients at high risk of lung cancer |
|
SOBERANA 01A |
|
OLIVO Study |
|
Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III. |
|
BIOMODULINA T in a long-lived population at high risk of COVID-19 infection |
|
Biomodulin T in older adult for protection in events of local transmission of COVID-19 |
|
Evaluation of the efficacy and safety of the potassium citrate tablet of immediate release vs Acalka® in urolithiasis in adults. |
|
SOBERANA 01 |
|
CIMAvax-EGF in Bladder cancer |
|
DALIA Study |
|
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America |
|
Transfer factor in Chronic Kidney Disease |
|
Biomodulina T in pediatric septic shock. Exploratory study |
|
Safety and immunogenicity of the CIGB 2020. |
|
Zinc-Children-Hospitalized-Pneumonia |
|
Second Line-Acute Asthma |
|
PLASMA TREATMENT TO ASYMPTOMATIC PATIENT WITH COVID-19 INFECTION |
|
Stem cells in patients with lung lesions (COVID-19) |
|
VIDA study |
